维普期刊资源整合服务平台（V6.5）

54篇 您的检索式：作者名="Weikersthal"

选中清除导出查看参考文献查看引证文献引用追踪共3页首页上一页第1页下一页末页 /3 跳转

	题名	作者	年代	出处	被引量
1	FOLFIRI联合西妥昔单抗或贝伐珠单抗治疗晚期结直肠癌:随机临床试验FIRE-3的最终生存及符合方案分析显示文摘背景:在FIRE-3研究中,与贝伐珠单抗+FOLFIRI相比,西妥昔单抗+FOLFIRI可提高KRAS野生型转移性结直肠癌(mCRC)的总生存率,但是未发现相应的无进展生存获益。本研究目的在于分析RAS野生型结直肠癌接受一线FOLFIRI治疗的可评价疗效患者中,与贝伐珠单抗相比,西妥昔单抗是否可改善治疗反应和生存情况,同时分析原发肿瘤部位对预后的影响。方法:意向治疗人群包括593例KRAS第2外显子野生型mCRC患者。进一步检测确认400名患者为全RAS野生型肠癌,其中352名(88%)患者接受了至少3个周期的治疗和至少1次基线后的影像检查以评估疗效,并纳入符合方案的患者(西妥昔单抗组169名,贝伐珠单抗组183名)。	何婉 HEINEMANN V VON WEIKERSTHAL L F DECKER T	2021	结直肠肛门外科2021，27，1：	11
2	FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial显示文摘	Volker Heinemann Ludwig Fischer von Weikersthal Thomas Decker Alexander Kiani Ursula Vehling-Kaiser Salah-Eddin Al-Batran Tobias Heintges Christian Lerchenmüller Christoph Kahl Gernot Seipelt Frank Kullmann Martina Stauch Werner Scheithauer J?rg Hielscher	2014	Lancet Oncology2014，，10：	2
3	AIO KRK0306,FIRE3 trial:CEA and CA19-9 influence outcome of patients with KRAS exon wild-type metastatic colorectal cancer(m CRC)receiving first-line therapy with FOLFIRI plus cetuximab or bevacizumab显示文摘	Michl M Fischer von Weikersthal L Crispin A	2014	J Clin Oncol2014，32，15：	1
4	A German mtdticenter, randomized phase III trial com- paring irinotecan - carboplatin with etoposide - carboplatin as first -line therapy for extensive -disease small -cell lung cancer 显示文摘	Schnfittel A Sebastian M Fischervon Weikersthal L et a/	2011	Am Oncol2011，22，8：	1
5	FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS:mutated tumours in the randomised German AIO study KRK-0306显示文摘	Stintzing S von Weikersthal L F Decker T	2012	Annals of oncology2012，23，7：	1
6	A ran- domized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small- cell lung cancer显示文摘	Schmittel A Fischer von Weikersthal L Sebastian M	2006	Ann Oncol2006，17，4：	1
7	FOLFIRI plus cetuximab versus FOLFIRI plus beva-cizumab as first-line treatment for patients with metastaticcolorectal cancer (FIRE-3): a randomised, open-label,phase 3 trial显示文摘	Heinemann V von Weikersthal LF Decker T	2014	Lancet Oncol2014，15，10：	1
8	FOLFIRI plus cetuximab versus FOLFIRI plus beva- cizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3) :a randomised,open-label, phase 3 trial显示文摘	Heinemann V Von Weikersthal LF Decker T	2014	Lancet Oncol2014，15，10：	1
9	Irinotecan plus carboplatin in extensive disease small cell lung cancer:a randomized phase Ⅱ trial显示文摘	Schmittel A L Fischer von Weikersthal M	2005	Clin Oncol2005，23，：	1
10	Early tumor shrinkage in metastatic colorectal cancer: retrospective analysis from an irinotecan - based randomized first - line trial 显示文摘	Giessen C Laubender RP Fischer yon Weikersthal L	2013	Cancer Sci2013，104，6：	1
11	A randomized phase Ⅱ trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer显示文摘	Schmittel A Fischer von Weikersthal L Sebastian M	2006	Ann Oncol2006，17，4：	1
12	A randomized phase II trial of irinotecan plus carboplatin ver sus etoposide plus carboplatin treatment in patients with ex tended disease small-cell lung cancer显示文摘	Schmittel A Fischer von Weikersthal L Sebastian M	2006	Ann Oncol2006，17，：	1
13	FOLFIRI plus eetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS:mutated tumours in the randomised German AIO study KRK-0306显示文摘	Stintzing S Fischer yon Weikersthal L Decker T et aI	2012	Ann Oncol2012，23，7：	1
14	Impact of subsequent therapies on outcome of the FIRE-3/AIO KRK0306 triM: First- line therapy with FOLFIRI plus Cetuximab or Bevacizumab in patients with KRAS wild- type tumors in metastatic colorectal cancer显示文摘	Modest DP Stintzing S van Weikersthal LF	2015	J Clin Oncol2015，33，32：	1
15	FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer(FIRE-3):a randomised,open-label,phase 3 trial显示文摘	Heinemann V von Weikersthal LF Decker T	2014	Lancet Oncol2014，15，10：	1
16	Phase Ⅲ trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer显示文摘	FISCHER VON WEIKERSTHAL L SCHALHORN A STAUCH M	2011	Eur J Cancer2011，47，2：	1
17	Irinotecan plus carboplatin versus etoposide plus carboplatin in extensive disease small cell lung cancer:Results of the German randomized phase Ⅲ trial显示文摘	Schmittel AH Sebastian M Fischer yon Weikersthal L		0，，：	1
18	FOLFIRI plus Cetuximab versus FOLFIRI plus Bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE- 3): A randomised, open-label, phase 3 trial显示文摘	Heinemann V von Weikersthal LF Decker T	2014	Lancet Oncol2014，15，10：	1
19	Independent radiological evaluation of objective response, early tumor shrinkage, and depth of response in FIRE-3 (AIO KRK- 0306) in the final RAS evaluable population 显示文摘	Stintzing S Modest DP Fischer von Weikersthal L	2014	Ann Oncol2014，25，4：	1
20	Randomized trial comparing cetuximab plus XELIRI versus cetuximab plus XELOX as first line treatment of patients with metastatic colorectal cancer (mCRC):a study of the german AIO CRC study group显示文摘	Heinemann V Fischer von Weikersthal L Vehling KU	2008	J Clin Oncol2008，，：	1

返回顶部每页显示：

共3页首页上一页第1页下一页末页 /3 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示